top of page

Research Roundup: Sep 19, 2022

Best of cannabinoid science this week...

In unvaccinated adults with COVID-19, PEA reduced their pro-inflammatory markers & caused an anti-inflammatory effect (hattip to Col. Dr. Michael Lewis)

Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial

In a review of cannabinoids & high blood pressure treatments, while the endocannabinoids did not help because of their contradictory actions, CBD effectively treated pulmonary hypertension

Why Multitarget Vasodilatory (Endo)cannabinoids Are Not Effective as Antihypertensive Compounds after Chronic Administration: Comparison of Their Effects on Systemic and Pulmonary Hypertension

A review of PEA for neurodegenerative disorders & defects of the brain’s white matter

Palmitoylethanolamide and White Matter Lesions: Evidence for Therapeutic Implications

A review of how the endocannabinoid system helps to control the hormonal & neuronal response to an immune challenge

Endocannabinoid System in the Neuroendocrine Response to Lipopolysaccharide-induced Immune Challenge

A review of why targeting the CB2 receptor is a key future of medicine (by Maccarrone et al.)

Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and Their Therapeutic Potential

A review of using cannabinoids to treat the orofacial pain of dentistry Cannabinoid Therapeutics in orofacial pain management: A Systematic Review

A review of working with the endocannabinoid system for ears, nose & throat specialists Endocannabinoid System and the Otolaryngologist

In gingival fibroblasts (the stem cells of your gums), CBD, CBG & CBDV had a range of anti-inflammatory & pro-inflammatory activities

Phytocannabinoids regulate inflammation in IL-1β-stimulated human gingival fibroblasts


bottom of page